NCT05442970 Cohort Study for Atrial Fibrillation Risk Stratification
| NCT ID | NCT05442970 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2013-06 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2013-06 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
AFHRI is planned as a prospective, single-center cohort study in patients at high risk of AF.
Eligibility Criteria
Inclusion Criteria: * Age 18 to 85 years; * Personally signed informed consent Exclusion Criteria: * Insufficient knowledge of the German language, in order to understand study documents and computer assisted interview without translation; * Physical or psychological incapability to cooperate in the investigations
Contact & Investigator
Renate B Schnabel, Prof.
✉ r.schnabel@uke.deRenate B Schnabel, Prof.
PRINCIPAL INVESTIGATOR
Department of Cardiology, University Medical Center Hamburg-Eppendorf
Frequently Asked Questions
Who can join the NCT05442970 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05442970 currently recruiting?
Yes, NCT05442970 is actively recruiting participants. Contact the research team at r.schnabel@uke.de for enrollment information.
Where is the NCT05442970 trial being conducted?
This trial is being conducted at Hamburg, Germany.
Who is sponsoring the NCT05442970 clinical trial?
NCT05442970 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The principal investigator is Renate B Schnabel, Prof. at Department of Cardiology, University Medical Center Hamburg-Eppendorf. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.